The impact of insulin administration during the mixed meal tolerance test

被引:16
作者
Besser, R. E. J. [1 ]
Jones, A. G. [1 ]
McDonald, T. J. [1 ,2 ]
Shields, B. M. [1 ]
Knight, B. A. [1 ]
Hattersley, A. T. [1 ]
机构
[1] Univ Exeter, Peninsula NIHR Clin Res Facil, Peninsula Med Sch, Exeter, Devon, England
[2] Royal Devon & Exeter NHS Fdn Trust, Dept Clin Biochem, Exeter, Devon, England
基金
美国国家卫生研究院;
关键词
BETA-CELL FUNCTION; PROTEIN PEPTIDE DIAPEP277; URINARY C-PEPTIDE; BLIND PHASE-II; DIABETES-MELLITUS; TREATED DIABETICS; TYPE-1; ONSET; GLUCAGON; SECRETION;
D O I
10.1111/j.1464-5491.2012.03649.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabet. Med. 29, 12791284 (2012) Abstract Aims The mixed meal tolerance test is the gold standard measure of endogenous insulin secretion. Practical issues limit the routine clinical use of this test, including omitting insulin prior to the ingestion of a high-carbohydrate liquid mixed meal, which can result in marked hyperglycaemia. We aimed to assess whether insulin omission is necessary during the mixed meal tolerance test and whether fasting C-peptide was a practical alternative to the test. Methods Ninety-one adults with insulin-treated diabetes (Type 1 n = 56, Type 2 n = 35) underwent two mixed meal tolerance tests; one standard without insulin and one with the patients usual morning insulin. Results The 90-min serum C-peptide was highly correlated in the standard mixed meal tolerance test and the test with insulin (r = 0.98, P < 0.0001). There was a 20% reduction in the peak C-peptide value when insulin was given {test with insulin [0.39 (0.011.16) vs. test without insulin 0.48 (0.011.36) nmol/l, P = 0.001]}, but the original serum C-peptide cut-off for significant endogenous insulin secretion (= 0.2 nmol/l) still correctly classified 90/91 patients (98% sensitivity/100% specificity). Fasting serum C-peptide was highly correlated to 90-min serum C-peptide during the test (r = 0.97, P < 0.0001). A fasting serum C-peptide = 0.07 nmol/l was the optimal cut-off (100% sensitivity and 97% specificity) for significant endogenous insulin secretion (defined as 90-min stimulated serum C-peptide = 0.2 nmol/l). Conclusions Insulin omission may not always be necessary during a mixed meal tolerance test and fasting serum C-peptide may offer a practical alternative in insulin-treated patients.
引用
收藏
页码:1279 / 1284
页数:6
相关论文
共 22 条
  • [1] Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes
    Agardh, CD
    Cilio, CM
    Lethagen, Å
    Lynch, K
    Leslie, RDG
    Palmér, M
    Harris, RA
    Robertson, JA
    Lernmark, Å
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) : 238 - 246
  • [2] DANEMAN D, 1987, CLIN INVEST MED, V10, P484
  • [3] DCCT Res Grp, 1987, J CLIN ENDOCR METAB, V65, P30
  • [5] FRIER BM, 1977, DIABETES, V26, P369
  • [6] CORRELATION BETWEEN FASTING SERUM C-PEPTIDE AND B-CELL INSULIN SECRETORY CAPACITY IN DIABETES-MELLITUS
    GARCIAWEBB, P
    BONSER, A
    WELBORN, TA
    [J]. DIABETOLOGIA, 1982, 22 (04) : 296 - 296
  • [7] CORRELATIONS BETWEEN FASTING PLASMA C-PEPTIDE, GLUCAGON-STIMULATED PLASMA C-PEPTIDE, AND URINARY C-PEPTIDE IN INSULIN-TREATED DIABETICS
    GJESSING, HJ
    MATZEN, LE
    FROLAND, A
    FABER, OK
    [J]. DIABETES CARE, 1987, 10 (04) : 487 - 490
  • [8] Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
    Greenbaum, Carla J.
    Mandrup-Poulsen, Thomas
    Friedenberg, Paula
    Battelino, Tadej
    Haastert, Burkhard
    Ludvigsson, Johnny
    Pozzilli, Paolo
    Lachin, John M.
    Kolb, Hubert
    [J]. DIABETES CARE, 2008, 31 (10) : 1966 - 1971
  • [9] Preservation of β-Cell Function in Autoantibody-Positive Youth With Diabetes
    Greenbaum, Carla J.
    Anderson, Andrea M.
    Dolan, Lawrence M.
    Mayer-Davis, Elizabeth J.
    Dabelea, Dana
    Imperatore, Giuseppina
    Marcovina, Santica
    Pihoker, Catherine
    [J]. DIABETES CARE, 2009, 32 (10) : 1839 - 1844
  • [10] Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes
    Greenbaum, CJ
    Harrison, LC
    [J]. DIABETES, 2003, 52 (05) : 1059 - 1065